TITLE

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

AUTHOR(S)
Kruis, W.; Frič, P.; Pokrotnieks, J.; Lukáš, M.; Fixa, B.; Kaščák, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.; Schulze, J.
PUB. DATE
December 2004
SOURCE
Gut;Dec2004, Vol. 53 Issue 12, p1617
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aim: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis. Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double dummy trial to receive either the probiotic drug 200 mg once daily (n = 162) or mesalazine 500 mg three times daily (n = 165). The study lasted for 12 months and patients were assessed by clinical and endoscopic activity indices (Rachmilewitz) as well as by histology. The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses. Results: The per protocol analysis revealed relapses in 40/110 (36.4%) patients in the E coli Nissle 1917 group and 38/112 (33.9%) in the mesalazine group (significant equivalence p = 0.003). Subgroup analyses showed no differences between the treatment groups in terms of duration and localisation of disease or pretrial treatment. Safely profile and tolerability were very good for both groups and were not different. Conclusions: The probiotic drug E coil Nissle 1917 shows efficacy and safely in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora.
ACCESSION #
18384791

 

Related Articles

  • Invasive Escherichia coli are a feature of Crohn's disease. Sasaki, Maiko; Sitaraman, Shanti V.; Babbin, Brian A.; Gerner-Smidt, Peter; Ribot, Efrain M.; Garrett, Nancy; Alpern, Joel A.; Akyildiz, Adil; Theiss, Arianne L.; Nusrat, Asma; Klapproth, Jan-Michael A. // Laboratory Investigation (00236837);Oct2007, Vol. 87 Issue 10, p1042 

    Crohn's disease (CD) and ulcerative colitis (UC) are idiopathic inflammatory conditions of the gut. Our goal was to investigate if invasive Escherichia coli strains were present in patients with inflammatory bowel disease (IBD). Bacterial strains were isolated from biopsy material obtained from...

  • New pharmaceuticals in inflammatory bowel disease. Łodyga, Michał; Eder, Piotr; Bartnik, Witold; Gonciarz, Maciej; Kłopocka, Maria; Linke, Krzysztof; Małecka-Panas, Ewa; Radwan, Piotr; Rydzewska, Grażyna // Gastroenterology Review / Przeglad Gastroenterologiczny;2015, Vol. 10 Issue 2, p57 

    This paper complements the previously published Guidelines of the Working Group of the Polish Society of Gastroenterology and former National Consultant in Gastroenterology regarding the management of patients with Crohn's disease and ulcerative colitis. Attention was focused on the new...

  • Modulating the human gut microbiome as an emerging therapeutic paradigm. RAJPAL, DEEPAK K.; BROWN, JAMES R. // Science Progress; 

    The human body is actually a vast and changing ecosystem comprised of billions of microbial organisms, known collectively as the microbiome. within the last few years, the study of the microbiome and its impact on human health has been a rapidly growing area of biomedical science. The gut...

  • Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. Nagy, Ferenc; Molnár, Tamás; Szepes, Zoltán; Farkas, Klaudia; Nyári, Tibor; Lonovics, János // World Journal of Gastroenterology;7/21/2008, Vol. 14 Issue 27, p4342 

    AIM: To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. METHODS: Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous...

  • The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. Naganuma, Makoto; Fujii, Toshimitsu; Watanabe, Mamoru // Journal of Gastroenterology;Feb2011, Vol. 46 Issue 2, p129 

    Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear...

  • Management of inflammatory bowel disease in poor responders to infliximab. Guerra, Iván; Bermejo, Fernando // Clinical & Experimental Gastroenterology;2014, Vol. 7, p359 

    Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an...

  • Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Kruis, W.; Frič, P.; Pokrotnieks, J.; Lukáš, M.; Fixa, B.; Kasščák, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C. // Gut;Nov2004, Vol. 53 Issue 11, p1617 

    Background and aim: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle...

  • Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. Burke, D.A.; Axon, A.T.R. // BMJ: British Medical Journal (International Edition);7/9/88, Vol. 297 Issue 6641, p102 

    Examines the incidence of escherichia coli (E. coli) in inflammatory bowel disease and infective diarrhea. Pathogenicity of the bacteria; Resistance of the bacteria to mannose; Expression of virulent antigens in the transfer of E. coli in vivo.

  • Abnormalities in colonic mucin may contribute to the persistence of colonic mucosal inflammation.  // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p71 

    Editorial. Deals with the possible contribution of the abnormalities in colonic mucin to the persistence of colonic mucosal inflammation. Percentage of ulcerative colitis patients with circulating antibodies to colonocytes; Number of reported mucin genes; Description of MUC2 mucin; Candidate...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics